Articles: 30.02 February 2019

Plans, partnerships, pacts and prescribing

In this editorial Rupert Payne, Consultant Editor for Prescriber, discusses the central role for pharmacists envisioned in the important policy documents, published in January 2019, that are likely to shape the face of primary care for the next few years

More details...

TheSocialMedwork: providing access to overseas medicines

TheSocialMedwork is an online service that helps patients across the world to access new medicines that are not approved in their own country. Joy Ogden talks to its founder and CEO Sjaak Vink about the service’s achievements, obstacles and long-term goals

More details...

Drug management in patients with reduced kidney function

Renal impairment can reduce drug excretion and increase the risk of adverse drug reactions. This article discusses the factors to consider when prescribing for patients with reduced kidney function or acute kidney injury.

More details...

Novel therapeutic targets in inflammatory bowel disease

SMAD7 antisense oligonucleotides and sphingosine-1-phosphate receptor modulators are new oral agents that are being investigated as potential treatments for inflammatory bowel disease (Crohn’s disease and ulcerative colitis). This article reports on some of the clinical trial outcomes so far

More details...

Developing new medicines for the treatment of pain

Because of the many problems with existing treatments, there is an urgent need for new pain medications, but the journey from drug development to the clinic is notoriously challenging, reports Sarah Houlton

More details...

Prescribing for patients with chronic fatigue syndrome

Chronic fatigue syndrome, also known as myalgic encephalomyelitis, can be difficult to both diagnose and treat, but there are many prescribed medications that can help with specific symptoms and co-morbidities. This article provides a guide to treatment in primary care

More details...

Benefits of a comprehensive COPD inhaler identification aid

A vast number of inhalers are available to treat COPD, and it is extremely difficult for both healthcare professionals and patients to keep track of them all. Karen Lee and Kamal Ibrahim from Bolton Hospital NHS Foundation Trust have therefore helped to develop a comprehensive COPD inhaler identification poster and here they discuss its usefulness in a range of clinical settings.

More details...

Ixekizumab: targeting plaque psoriasis and psoriatic arthritis

Ixekizumab (Taltz) is an anti-interleukin-17A monoclonal antibody therapy for the treatment of adults with plaque psoriasis or psoriatic arthritis. This article discusses its efficacy and place in therapy

More details...

Web design and marketing agency Leamington Spa